S Cannavo1, F Bogazzi2, A Colao3, L De Marinis4, P Maffei5, R Gomez6, E Graziano7, M Monterubbianesi7, S Grottoli8. 1. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. 2. Department of Endocrinology and Metabolic Diseases, Ospedale Cisanello, Pisa, Italy. 3. Endocrinological Clinic, Departmeno of Endocrinology and Molecular and Clinic Oncology, Policlinico Universitario Federico II, Naples, Italy. 4. Institute of Endocrinology, Cattolica del Sacro Cuore University, Policlinico A. Gemelli, Rome, Italy. 5. III Medical Clinic, Department of Medicine, Azienda Ospedaliera di Padova, Padua, Italy. 6. Pfizer Europe Medical Affairs, Endocrinology, Puurs, Belgium. 7. Pfizer Italia, Medical Department Endocrinology, Rome, Italy. 8. Department of Medicine, Division of Endocrinology, Diabetology and Metabolism, Città della, Salute e della Scienza di Torino, University of Torino, Turin, Italy. silvia.grottoli@unito.it.
Abstract
OBJECTIVE: GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safety surveillance study of long-term pegvisomant treatment of patients with acromegaly. A noninterventional safety surveillance study in which safety and treatment outcomes of pegvisomant were evaluated on the basis of data collected during a 7-year period. METHODS: A total of 204 acromegaly patients treated by seven centers enrolling 16-49 patients each (group A) and 137 subjects by 18 centers following 3-14 cases ( group B). RESULTS: Patients of group A and B were treated for 4.4 ± 2.7 and 4.2 ± 2.2 years, respectively. IGF-1 ULN normalized in 64.4 % (n = 56) and 54.4 % (n = 31) in group A and B, respectively, after 1-year treatment, and in 57.3 % (n = 106) and 72.5 % (n = 87) at last visit. Starting doses were significantly higher in group A. They were progressively increased during treatment in both groups, but were higher in uncontrolled patients than in controlled ones only in group A. Reported adverse events were more frequent, and the prevalence of patients with adverse events was higher in group B. CONCLUSIONS: On the basis of this original study approach, we could speculate that in the centers in which more patients are treated with pegvisomant, less adverse events are reported, but the long-term effectiveness is lower than in centers with less cases, perhaps because of an inadequate patient's selection.
OBJECTIVE:GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safety surveillance study of long-term pegvisomant treatment of patients with acromegaly. A noninterventional safety surveillance study in which safety and treatment outcomes of pegvisomant were evaluated on the basis of data collected during a 7-year period. METHODS: A total of 204 acromegalypatients treated by seven centers enrolling 16-49 patients each (group A) and 137 subjects by 18 centers following 3-14 cases ( group B). RESULTS:Patients of group A and B were treated for 4.4 ± 2.7 and 4.2 ± 2.2 years, respectively. IGF-1 ULN normalized in 64.4 % (n = 56) and 54.4 % (n = 31) in group A and B, respectively, after 1-year treatment, and in 57.3 % (n = 106) and 72.5 % (n = 87) at last visit. Starting doses were significantly higher in group A. They were progressively increased during treatment in both groups, but were higher in uncontrolled patients than in controlled ones only in group A. Reported adverse events were more frequent, and the prevalence of patients with adverse events was higher in group B. CONCLUSIONS: On the basis of this original study approach, we could speculate that in the centers in which more patients are treated with pegvisomant, less adverse events are reported, but the long-term effectiveness is lower than in centers with less cases, perhaps because of an inadequate patient's selection.
Entities:
Keywords:
Acromegaly; GH; Hub and spoke; IGF-1; Pegvisomant
Authors: M Filopanti; L Olgiati; G Mantovani; S Corbetta; M Arosio; V Gasco; L De Marinis; C Martini; F Bogazzi; S Cannavò; A Colao; D Ferone; G Arnaldi; F Pigliaru; A Peri; G Angeletti; M L Jaffrain-Rea; A G Lania; A Spada Journal: J Clin Endocrinol Metab Date: 2011-12-07 Impact factor: 5.958
Authors: N García Basavilbaso; M Guitelman; A Nagelberg; G Stalldecker; A Carabelli; O Bruno; K Danilowitz; M Manavela; S Mallea Gil; C Ballarino; R Guelman; D Katz; S Fidalgo; R Leal; H Fideleff; M Servidio; D Bruera; F Librandi; A Chervin; M Vitale; A Basso Journal: Front Horm Res Date: 2010-07-05 Impact factor: 2.606
Authors: Pietro Maffei; Chiara Martini; Claudio Pagano; Nicola Sicolo; Francesco Corbetti Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2007-09 Impact factor: 4.256
Authors: A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner Journal: Lancet Date: 2001-11-24 Impact factor: 79.321
Authors: Antonio Bianchi; Gherardo Mazziotti; Laura Tilaro; Vincenzo Cimino; Flora Veltri; Eleonora Gaetani; Giovanni Pecorini; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis Journal: Pituitary Date: 2009 Impact factor: 4.107
Authors: B L Herrmann; M Severing; A Schmermund; C Berg; Th Budde; R Erbel; K Mann Journal: Exp Clin Endocrinol Diabetes Date: 2009-04-16 Impact factor: 2.949
Authors: M Ragonese; S Grottoli; P Maffei; A Alibrandi; M R Ambrosio; G Arnaldi; A Bianchi; S Puglisi; M C Zatelli; L De Marinis; E Ghigo; A Giustina; F Maffezzoni; C Martini; L Trementino; S Cannavo Journal: J Endocrinol Invest Date: 2017-10-28 Impact factor: 4.256
Authors: T Apaydin; H M Ozkaya; F E Keskin; O A Haliloglu; K Karababa; S Erdem; P Kadioglu Journal: J Endocrinol Invest Date: 2016-10-20 Impact factor: 4.256
Authors: A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo Journal: J Endocrinol Invest Date: 2017-02-07 Impact factor: 4.256